Safety of intranasal steroids (multiple letters)

Journal of Allergy and Clinical Immunology

Volumn 103, Issue 2 I, 1999, Pages 353-354

  Bachert, C ^a   Lipworth, B J ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE;

CORTICOSTEROID THERAPY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SAFETY; HUMAN; HYDROCORTISONE BLOOD LEVEL; LETTER; PRIORITY JOURNAL; RHINITIS;

EID: 0033048621     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(99)70514-2     Document Type: Letter

References (4)

1. PU Knutsson P Stierna C Marcus J Carlstedt-Duke K Carlstrom M Bronnegard Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function J Endocrinol 144 1995 301 310
2. A Foresi A Pelucchi G Gherson B Mastropasqua A Chiapparino R Testi Once daily intranasal fluticasone propionate (200 μg) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis J Allergy Clin Immunol 98 1996 274 282
3. LJ Wood MD Inman JA Denburg PM OByrne Allergen challenge increases cell traffic between bone marrow and lung Am J Respir Cell Mol Biol 18 1998 759 767
4. P Daley-Yates T McAllister Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations Allergy 53 Suppl 43 1998 412